Lamivudine/tenofovir disoproxil fumarate + nevirapine - Mylan PharmaceuticalsAlternative Names: Tenofovir disoproxil fumarate/lamivudine + nevirapine - Mylan Pharmaceuticals
Latest Information Update: 23 Jul 2015
At a glance
- Originator Mylan Pharmaceuticals
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preregistration HIV-1 infections